1. Home
  2. CYTK vs BCC Comparison

CYTK vs BCC Comparison

Compare CYTK & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • BCC
  • Stock Information
  • Founded
  • CYTK 1997
  • BCC 2004
  • Country
  • CYTK United States
  • BCC United States
  • Employees
  • CYTK N/A
  • BCC N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • BCC RETAIL: Building Materials
  • Sector
  • CYTK Health Care
  • BCC Consumer Discretionary
  • Exchange
  • CYTK Nasdaq
  • BCC Nasdaq
  • Market Cap
  • CYTK 6.0B
  • BCC 5.3B
  • IPO Year
  • CYTK 2004
  • BCC 2013
  • Fundamental
  • Price
  • CYTK $48.18
  • BCC $140.67
  • Analyst Decision
  • CYTK Buy
  • BCC Buy
  • Analyst Count
  • CYTK 16
  • BCC 5
  • Target Price
  • CYTK $83.67
  • BCC $139.60
  • AVG Volume (30 Days)
  • CYTK 1.2M
  • BCC 259.7K
  • Earning Date
  • CYTK 11-06-2024
  • BCC 11-04-2024
  • Dividend Yield
  • CYTK N/A
  • BCC 0.30%
  • EPS Growth
  • CYTK N/A
  • BCC N/A
  • EPS
  • CYTK N/A
  • BCC 10.21
  • Revenue
  • CYTK $3,219,000.00
  • BCC $6,801,070,000.00
  • Revenue This Year
  • CYTK N/A
  • BCC N/A
  • Revenue Next Year
  • CYTK $911.39
  • BCC $5.28
  • P/E Ratio
  • CYTK N/A
  • BCC $13.44
  • Revenue Growth
  • CYTK N/A
  • BCC N/A
  • 52 Week Low
  • CYTK $30.68
  • BCC $106.38
  • 52 Week High
  • CYTK $110.25
  • BCC $154.67
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 39.67
  • BCC 47.07
  • Support Level
  • CYTK $49.64
  • BCC $138.87
  • Resistance Level
  • CYTK $59.39
  • BCC $145.50
  • Average True Range (ATR)
  • CYTK 2.23
  • BCC 4.57
  • MACD
  • CYTK -0.54
  • BCC -0.14
  • Stochastic Oscillator
  • CYTK 4.88
  • BCC 57.49

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About BCC Boise Cascade L.L.C.

Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two segments namely Wood Products and Building Materials Distribution. Wood Products segment manufactures EWP, consisting of laminated veneer lumber (LVL), I-joists, and laminated beams. The Building Materials Distribution segment is engaged in the wholesale of building materials. It distributes products such as plywood, OSB, and lumber items such as siding, doors, metal products, insulation, and roofing, EWP and others. The company generates a majority of its revenue from the Building Material Distribution segment.

Share on Social Networks: